Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan.
Anticancer Res. 2010 Sep;30(9):3391-5.
Bevacizumab is a specific inhibitor of angiogenesis and a neutralising antibody against vascular endothelial growth factor (VEGF). The effect of bevacizumab was evaluated on malignant fibrous histiocytoma (MFH) in vivo using an animal model.
MFH cell line, NaraH, was implanted to athymic nude mice which were randomly divided into a treatment and a control group. The change in body weight and tumour volume were evaluated and immunohistochemical analysis was performed of microvessel density (MVD) and VEGF expression in the tumour tissue.
Bevacizumab significantly induced inhibition of tumour growth, reducing tumour volume to 48% at the end of experiment. Intratumoural MVD was significantly decreased in the bevacizumab treatment group compared to the control group. A positive correlation was found between tumour volume and MVD.
Bevacizumab suppressed MFH tumour growth by inhibiting tumoural angiogenesis. The current study suggests that bevacizumab may be a novel therapeutic agent for MFH.
贝伐单抗是一种血管生成的特异性抑制剂，也是血管内皮生长因子（VEGF）的中和抗体。本研究采用动物模型评估贝伐单抗对恶性纤维组织细胞瘤（MFH）的体内作用。
将 NaraH 纤维组织细胞瘤株接种于裸鼠，随机分为治疗组和对照组。观察两组裸鼠的体重变化和肿瘤体积，并对肿瘤组织进行微血管密度（MVD）和 VEGF 表达的免疫组化分析。
贝伐单抗能显著抑制肿瘤生长，实验结束时肿瘤体积缩小至 48%。与对照组相比，贝伐单抗治疗组肿瘤内 MVD 明显降低。肿瘤体积与 MVD 呈正相关。
贝伐单抗通过抑制肿瘤血管生成抑制 MFH 肿瘤生长。本研究提示贝伐单抗可能是治疗 MFH 的一种新的治疗药物。
